Wednesday, April 22, 2020

8:00 AM - 10:00 AM

OPENING PLENARY SESSION (517A)

Primary Audience: ALL

Chairs: Stuart Sweet, MD and Stephan Ensminger, MD, DPhil

8:00 AM Welcome/Program Chair Report

Stephan Ensminger, MD, DPhil, University Herzzentrum Lubeck, Lubeck, Germany

8:10 AM Thoracic Registry Report

Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

8:20 AM IMACS Registry Report

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

8:30 AM Journal Editor's Report

Mandeep R. Mehra, MD, FRCP, FACC, FESC. Brigham and Women's Hospital, Boston, MA, USA

8:40 AM President's Report

Stuart Sweet, MD, St. Louis Children's Hospital, St. Louis, MO, USA

8:55 AM Michael Hess Lifetime Achievement Commemoration

David O. Taylor, MD, Cleveland Clinic, Cleveland, OH, USA

9:00 AM Featured Abstract

9:20 AM MAID (Medical Assistance in Dying): Implications for Transplantation

James Downar, MDCM, MHSc, FRCPC, University of Ottawa, Ottawa, ON, Canada

9:40 PM Featured Abstract

SYMPOSIUM 01: Big Brother is Watching You! Home-Monitoring and Technical Advances in VAD Therapy (517A)

Primary Audience: MCS

Secondary Audience: NHSAH

Symposium 1 Big Brother is Watching You! Home-Monitoring and Technical Advances in VAD Therapy (517A)

Session Summary: Long-term mechanical circulatory support improves outcome and quality of life of patients with advanced heart failure. There is growing evidence that home-monitoring of patients with a ventricular assist device (VAD) may impact outcome. In addition, recent innovations in powering devices and both internal and external device management have advanced VAD therapy. In this session, the role of home-monitoring of VAD patients and recent innovations in VAD technology will be discussed.

Chairs: Kathleen Grady, PhD, APN, FAAN and Laurens Tops, MD

10:30 AM When the Beat Goes On: Monitoring of Arrhythmias in VAD Patients

Gabriel Sayer, MD, University of Chicago, Chicago, IL, USA

10:45 AM Forgotten No More? Use of Hemodynamics in Monitoring and Optimization of VAD Patients

Eugene C. DePasquale, MD, Keck School of Medicine of USC, Los Angeles, CA, USA

11:00 AM Of Cuff and Doppler: (Home-)Monitoring of Blood Pressure in VAD Patients

Van-Khue Ton, MD, PhD, Massachusetts General Hospital, Boston, MA, USA

11:15 AM It’s All About Coordination: The VAD Coordinator’s Perspective on Home-Monitoring

Thomas Schlöglhofer, MSc, Medical University of Vienna, Vienna, Austria

11:30 AM Of Apps and Icons: Utilizing Smart Phones and Tablets to Enhance Patient Monitoring

Jesus Casida, PhD, RN, Johns Hopkins University, Baltimore, MD, USA

11:45 AM Innovations in Mechanical Circulatory Support

Yuriy Pya, MD, National Res Center for Cardiac Surgery, Astana, Kazakhstan

12:00 PM Panel Discussion

Primary Audience: HF/HTX

Secondary Audience: MCS, PEDS, PH, PHARM

Symposium 2 The Evolving Science of Shock Recognition and Management (210EF)

Session Summary: This session aims to review the evolving understanding of cardiogenic shock, including its varied presentations and trajectories, the importance of hemodynamic data in management, determination of treatment options, and the rapidly growing concept of multidisciplinary shock teams to deliver expedited and patient-centered care.

Chairs: Shelley Hall, MD, FACC, FHFSA, FAST and Peter Macdonald, MD, PhD

10:30 AM From Code STEMI to Code Shock: Early Recognition is Key

Anique Ducharme, MD, MSC, Montreal Heart Institute, Montreal, QC, Canada

10:45 AM Hemodynamics Drive Treatment Choices

Jan F. Gummert, MD, PhD, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany

11:00 AM Let the Tissue Breathe: Use of Biomarkers to Optimize Organ Perfusion

Sandra V. Chaparro, MD, University of Miami, Miami, FL, USA

11:15 AM Drug Therapy for Cardiogenic Shock: Which, When, and How

Douglas Greig, MD, Pontificia Universidad Católica de Chile, Santiago, Chile

11:30 AM ECMO and Other Demons: How to Choose the Circulatory Support System in Cardiogenic Shock

Jonathan W. Haft, MD, University of Michigan, Ann Arbor, MI, USA

11:45 AM Teamwork Makes the Dream Work: Evolution of the Shock Team

Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada

12:05 PM Panel Discussion

Symposium 3 Crossing the HLA Rubicon: Lung Transplantation in the Presence of Donor Specific Antibodies (511)

Primary Audience: LF/LTX

Secondary Audience: BSTR, NHSAH, PATH, PEDS, PHARM

Session Summary: Highly sensitized lung transplant candidates have prolonged waitlist times and increased waitlist mortality. This symposium will include representatives from programs that differ in their approaches to achieving successful transplant outcomes in this population.

Chairs: Tanya McWilliams, MD and Andrew Courtwright, MD

10:30 AM Not All Created Equal: Which Pre-Transplant DSAs Really Matter?

Elaine F. Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA, USA

10:45 AM DEBATE: Desensitization is an Effective Bridge to Lung Transplant (PRO)

Ramsey Hachem, MD, Washington University School of Medicine, Saint Louis, MO, USA

11:00 AM DEBATE: Desensitization is an Effective Bridge to Lung Transplant (CON)

Antoine Roux, MD, Foch Hospital, Paris, France

11:15 AM It's Time to Include Testing for Non-HLA Antibody in Thoracic Transplantation

Nancy Reinsmoen, MD, Cedars Sinai Health System, Los Angeles, CA, USA

11:30 AM Pheresis Your Fears Away (In The OR)

Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, ON, Canada

11:45 AM You Must Augment: Induction and Maintenance Immunosuppression When Crossing DSA

Glen Westall, MD, The Alfred Hospital, Melbourne, Australia

12:00 PM Panel Discussion

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

12:15 PM - 2:00 PM

Lunch Break

2:00 PM – 3:45 PM

SYMPOSIUM 04: We Are the World: Building Transplant Programs Internationally (210EF)

Primary Audience: HF/HTX

Secondary Audience: LF/LTX, MCS, PEDS

Session Summary: Heart transplant (HTx) volume has plateaued internationally, yet the waiting lists continue to grow. This dilemma affects both HTx-developed and developing countries uniquely. Developing countries struggle with ethical/legal/cultural factors to establish socially-acceptable programs. This session aims to identify barriers and solutions to dilemmas that various HTx programs face worldwide.

Chairs: Tomoko S. Kato, MD, PhD and Javier Segovia, MD, PhD

2:00 PM Nothing’s Gonna Stop Us Now: Challenges of Growing a Transplant Program

Sonia Mirabet, MD, Hospital Sant Pau, Barcelona, Spain

2:15 PM Current Status and Challenges of Setting Up Transplant Programs in India

Nandkishore Kapadia, MBBS, MS, MCh, PhD, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

2:30 PM Current Status and Challenges in the Management of Advanced Heart Failure in China and Southeast Asia

Cumara C. Sivathasan, MBBS, FRCS, National Heart Centre, Singapore, Singapore

2:45 PM Current Status and Challenges in the Management of Advanced Heart Failure in Korea and Japan

Takeshi Nakatani, MD, PhD, Maki Hospital / Maki Health Care Group, Osaka, Japan

3:00 PM Current Status and Challenges in the Management of Advanced Heart Failure in South America

Adriana Torres, MD, Fundacion Cardioinfantil, Bogota, Colombia

3:15 PM We Are Family: How Developed and Developing Nations Can Work Together

Stephen C. Clark, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

3:30 PM Panel Discussion

SYMPOSIUM 05: Immunology of Aging in Thoracic Transplantation and MCS (510BD)

Primary Audience: BSTR

Secondary Audience: HF/HTX, LF/LTX, MCS, PATH, PHARM

Session Summary: Older thoracic transplant and mechanical circulatory support patients have increased rates of infection and death compared with younger patients, demonstrating the important of age-associated immune dysfunction in the growing numbers of older candidates. At the same time, older patients have lower rates of rejection compared with younger patients. This symposium seeks to explore differences across a variety of immunologic lineages, leading to a concept of biologic rather than chronologic age.

Chairs: Hanneke M. Kwakkel-van Erp, MD, PhD and John McDyer, MD

2:00 PM Setting the Stage: Aging Trends in Thoracic Transplant and MCS

John McDyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

2:10 PM Biology of T Cell Aging: Senescence and Exhaustion

Joanna M. Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

2:25 PM Q & A

2:29 PM B Cells, Aging and Impact on Transplantation

Marilia Cascalho, MD, PhD, University of Michigan Hospital, Ann Arbor, MI, USA

2:44 PM Q & A

2:48 PM NK Cells, Aging, and Tolerance in Transplantation

Daniel Calabrese, MD, UCSF Medical Center, San Francisco, CA, USA

3:03 PM Q & A

3:07 PM ”Inflammaging” and the Older Transplant Patient: Role of Cytokines and Chemokines in Infection and Rejection

John A. Belperio, MD, UCLA Pulmonary and Critical Care Medicine, Los Angeles, CA, USA

3:22 PM Q & A

3:26 PM Continuous Flow Ventricular Assist Devices and Cellular Aging

Maja-Theresa Dieterlen, PhD, Herzzentrum Leipzig, Leipzig, Germany

3:41 PM Q & A

SYMPOSIUM 06: Hot Topics for Transplant and MCS Clinicians: Burnouot, #SoMe and Psychosocial Issues (510AC)

Primary Audience: ALL

Session Summary: This session focuses on hot topics relevant to transplant and MCS clinicians of all disciplines, including provider burnout and resilience, social media use among transplant professionals, and pressing psychosocial issues. This session will feature a physician’s own personal story of heart transplantation and transformation,- after months of attributing heart failure symptoms to the busy lives we lead as healthcare providers!

Chairs: Michael Petty, PhD, RN, CNS and Heike Spaderna, PhD

2:00 PM From My Heart: A Physician’s Personal Story of Transplant and Transformation

Alin Gragossian, DO, Drexel University, Philadelphia, PA, USA

2:15 PM A Hard Day at Work: Provider Burnout and Resilience in Transplant Medicine

Melissa Cousino, PhD, C.S. Mott Children's Hospital, Ann Arbor, MI, USA

2:30 PM #SoMe, So What? Should the Transplant Community Embrace Social Media?

Brian Keller, MD, PhD, The Ohio State University, Columbus, OH, USA

2:45 PM Self-Management Interventions: What Really Works?

Christiane Kugler, PhD, Albert-Ludwigs-University Freiburg, Dortmund, Germany

3:00 PM DEBATE: Ready to Launch! Our Young Adults Must Transition (PRO)

Jenna Murray, MSN, RN, CPNP-AC, Lucile Packard Children’s Hospital, Palo Alto, CA, USA

3:15 PM DEBATE: Ready to Launch! Our Young Adults Must Transition (CON)

Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL, USA

3:30 PM Panel Discussion

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

3:45 PM – 4:15 PM

Coffee Break

SYMPOSIUM 07: Success Starts at the Beginning: Improving Outcomes From Referral to Implant and Beyond (517A)

Primary Audience: MCS

Secondary Audience: HF/HTX, NHSAH, PEDS

Session Summary: The purpose of this session is to discuss the process that surrounds mechanical circulatory support including when to refer, initial evaluation for candidacy, optimization before implant and management of patients following MCS therapy. In this session we will discuss various challenges and perspectives of the multidisciplinary team and how to best prepare the patients for positive outcomes.

Chairs: Colleen J. Juricek-LaBuhn, RN, MSN and Erin Davis, RN

4:15 PM Early Identification of Advancing Heart Failure: Knowing When To Refer

Bow (Ben) Chung, MD, University of Chicago, Chicago, IL, USA

4:30 PM Evaluation for Candidacy: Can We Optimize for Better Results?

Tonya I. Elliott, MSN, RN, CCTC, CHFN, MedStar Washington Hospital Center, Reston, VA, USA

4:45 PM Looking at Candidacy Though a Different Lens: The Psychosocial Perspective

Jill Giordano, LCSW, Newark Beth Israel Medical Center, Newark, NJ, USA

5:00 PM Can Early Education Be the Start of Success?

Keaton Lloyd, University of Alabama in Birmingham, Birmingham, AL, USA

5:15 PM What Role Does Medical Optimization Play in Surgical Implantation?

Antonio Loforte, MD, S. Orsola Hospital, Bologna, Italy

5:30 PM Adverse Events and How to Achieve Successful Management and Long Term Outcomes

Sarah Schettle, PA-C, Mayo Clinic, Rochester, MN, USA

5:45 PM Panel Discussion

SYMPOSIUM 08: Like a Bridge Over Troubled Waters: Preoperative Assessment and Management of Pulmonary Hypertension (516BC)

Primary Audience: PH

Secondary Audience: CTEPH, HF/HTX, PEDS

Session Summary: Patients with PH are at higher risk for adverse outcomes in elective and non-elective surgery. This session reviews pre-operative risk assessment and the evaluation and management of patients and the intra-operative and post-operative consideration to minimize adverse outcomes. The role of peri-operative MCS is explored. The session will include a debate on the role of PAC monitoring. This symposium heralds the ISHLT expert consensus document currently under development. A panel discussion with all speakers will conclude this session.

Chairs: Marc Simon, MD and Teresa De Marco, MD

4:15 PM The Calm Before the Storm: Preoperative Evaluation and Management

Dana McGlothlin, MD, Kaiser Permanente, San Francisco, CA, USA

4:30 PM The Raging Storm: Intraoperative Considerations and Management

Karen M. McRae, MD, Toronto General Hospital, Toronto, ON, Canada

4:45 PM The Aftermath: Postoperative Considerations and Management

Oksana A. Shlobin, MD, Inova Fairfax Hospital, Falls Church, VA, USA

5:00 PM Tread Carefully: Patient with Eisenmenger's Undergoing Surgery

Erika Berman-Rosenzweig, MD, Columbia University Hospital, New York, NY, USA

5:15 PM DEBATE: PAC Monitoring is Essential in the Management of the High Risk PAH Patient Undergoing Surgery (PRO)

Celine Dewachter, MD, Erasme Hospital, Brussels, Belgium

5:30 PM DEBATE: PAC Monitoring is Essential in the Management of the High Risk PAH Patient Undergoing Surgery (CON)

Stuart Hastings, MBBS, The Alfred Hospital, Melbourne, Australia

5:45 PM Panel Discussion

SYMPOSIUM 09: Eye Ball Test! I know My Patient is Frail: Now What? (511)

Primary Audience: LF/LTX

Secondary Audience: HF/HTX, MCS, NHSAH, PEDS

Session Summary: Patients with end stage heart and lung disease are frequently identified as frail and this is predictive of worse outcomes. Currently the best management for these patients is unclear. This session will describe current evidence gleaned from across medical specialties to manage the frail patient in all facets of the phenotype. The session will highlight ongoing relevant trials and will culminate in a debate on the use of frailty as criteria to guide listing for transplant.

Chairs: Goran Dellgren, MD and Cassie Kennedy, MD

4:15 PM Iron Man (or Woman): Targeting Frailty Before Lung Transplantation

Aida Venado, MD, UCSF Medical Center, San Francisco, CA, USA

4:30 PM The Incredible Bulk: Addressing Obesity and Body Composition Pre-Transplant

Michaela Anderson, MD, Columbia University, New York, NY, USA

4:45 PM Frontiers of the Mind: Psychologic Frailty

Katharina Tigges-Limmer, PhD, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany

5:00 PM DEBATE: The Pre-Frail Patient Should Be Considered Earlier for Listing (PRO)

Hanneke Kwakkel-van Erp, MD, University Hospital, Antwerp, Belgium

5:15 PM DEBATE: The Pre-Frail Patient Should Be Considered Earlier for Listing (CON)

Allan Glanville, MD, St Vincent's Hospital, Sydney, Australia

5:30 PM Endgame: When to Delist

Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA

5:45 PM Panel Discussion

SYMPOSIUM 10: JHLT at ISHLT: The Year in a Capsule (210AB)

Primary Audience: ALL

Session Summary: This session will review the most impactful papers published in Journal of Heart and Lung Transplantation (JHLT) over the past year, among a broad field of interest: heart and lung transplantation, mechanical circulatory support, pediatric transplantation, infectious diseases. After a presentation of the main papers by a junior faculty, an expert senior member will comment how they significantly contributed to change the current knowledge and practice.

Chairs: Marco Masetti, MD, PhD and Peter Hopkins, MD

4:15 PM JHLT Best Papers of the Year

Patricia Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

4:30 PM Highlights of Heart Transplantation and MCS

Agnieszka Ciarka, MD, PhD, Catholic University of Leuven, Leuven, Belgium

4:45 PM Invited Discussant in Heart Transplantation and MCS

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

4:52 PM Highlights of Lung Transplantation and Pulmonary Hypertension

Joshua Mooney, MD, Stanford University School of Medicine, Stanford, CA, USA

5:07 PM Invited Discussant in Lung Transplantation and Pulmonary Hypertension

Lorriana E. Leard, MD, UCSF Medical Center, San Francisco, CA, USA

5:14 PM Highlights of Pediatric Heart and Lung Transplantation

Kyle D. Hope, MD, Texas Children’s Hospital, Houston, TX, USA

5:29 PM Invited Discussant in Pediatric Heart and Lung Transplantation

David Morales, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA

5:36 PM Highlights of Infectious Diseases

Nicole Pagani, MD, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

5:51 PM Invited Discussant in Infectious Diseases

Paolo A. Grossi, MD, PhD, University of Insubria, Varese, Italy

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

6:00 PM – 7:15 PM

POSTER SESSION 01

Information on ISHLT2020 Poster Sessions will be available in January 2020

Thursday, April 23, 2020

SUNRISE SYMPOSIUM 01: Cardiac Anesthesia: Tales from the Other Side of the Ether Screen (517A)

Primary Audience: MCS

Secondary Audience: HF/HTX, LF/LTX, PEDS, PH

Session Summary: The intraoperative management of patients undergoing mechanical circulatory support is challenging, multidisciplinary, and involves several aspects of patient care. This session addresses topics of paramount importance in the intraoperative period with tremendous impact on the outcome of the patients undergoing mechanical circulatory support.

Chairs: Sharon McCartney, MD and Anna Meyer, MD

7:00 AM When the Right Goes Wrong: Right Ventricle Failure in VAD Placement - Intraoperative Pearls

Alina Nicoara, MD, Duke University, Durham, NC, USA

7:15 AM Management of Coagulopathy During VAD Placement: Bleed Now or Clot the Pump Later?

Angela Maria Rajek, MD, Medical University of Vienna, Vienna, Austria

7:30 AM Vasoplegia Syndrome Complicating Failure

Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Bucaramanga, Colombia

7:45 AM Panel Discussion

SUNRISE SYMPOSIUM 02: Primary Graft Dysfunction after Heart Transplantation: PCD or Predictor of Given Death? (210EF)

Primary Audience: HF/HTX

Secondary Audience: MCS, PEDS, PHARM

Session Summary: This session will describe and explore the range of acute graft dysfunction seen following heart transplantation. The talks outlines the definition, diagnostic tools, treatment options and outcomes for primary graft dysfunction. The speakers will examine the limitations of current understanding and review potential new or innovative approaches to tackle this important problem. A panel discussion with all speakers will conclude this session.

Chairs: Monica M. Colvin, MD and Fabiana G. Marcondes-Braga, MD, PhD

7:00 AM Primary Graft Dysfunction: What's In A Name?

Maryjane Farr, MD, Columbia University, New York, NY, USA

7:15 AM Primary Graft Dysfunction: Who's To Blame?

Jong-Chan Youn, MD, PhD, Hallym University, Gyeonggido, Republic of Korea

7:30 AM Management of Primary Graft Dysfunction: What's Cool, What's Not?

Pedro Catarino

SUNRISE SYMPOSIUM 03: Building on a Solid Foundation: Guidelines an Unique Challenges in CF Lung Transplant (511)

Primary Audience: LF/LTX

Secondary Audience: NHSAH, PEDS, PHARM

Session Summary: The focus of this session is to provide an in-depth assessment of CF specific considerations in lung transplant. Recently published referral guidelines will be reviewed with a focus on issues such as adherence and psychosocial factors. Identification of at-risk patients and strategies to enhance waitlist survival will be undertaken. CF specific pre transplant issues and how they influence candidacy will be reviewed including liver disease, non adherence, vascular anatomy and other GIT manifestations.

Chairs: Monique Malouf, MD and Cecilia Chaparro, MD

7:00 AM Optimizing Transplant Referral for CF Patients Using Cystic Fibrosis Foundation Referral Guidelines

Carli Lehr, MD, Cleveland Clinic, Cleveland, OH, USA

7:20 AM Medical Strategies to Improve CF Survival to Lung Transplant

Whitney Brown, MD, Inova Fairfax Hospital, Falls Church, VA, USA

7:35 AM Unique Pre-Transplant Non-Microbiological Considerations for CF Lung Transplant Candidates

Christian Benden, MD, FCCP, University Hospital Zurich, Zurich, Switzerland

7:50 AM Panel Discussion

SUNRISE SYMPOSIUM 04: Portopulmonary Rhapsody: Everything You Need to Know about Portopulmonary Hypertension (210AB)

Primary Audience: PH

Secondary Audiences: CTEPH

Session Summary: This session will review the new topics in the literature regarding portopulmonary hypertension. It will review the pathogenesis of portopulmonary hypertension and other forms of PAH related to liver disease, it will review the emerging treatment options for patients with portopulmonary hypertension, and will include a great debate on role of liver transplantation in treatment of portopulmonary hypertension.

Chairs: Nicholas A. Kolaitis, MD and Daniel H. Kim, MD

7:00 AM Case Presentation: RVSP"itis": Patient with Newly Diagnosed Portopulmonary Hypertension

Sophia Airhart, MD, University of Arizona, Tucson, AZ, USA

7:05 AM There Goes the Neighborhood: Updates in Pathogenesis, Epidemiology and Treatment of Portopulmonary Hypertension

Olivier Sitbon, MD, Hopital Universitaire de Bicêtre, Paris Sud, France

7:20 AM DEBATE: Liver Transplantation is a Treatment For Portopulmonary Hypertension (PRO)

Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN, USA

7:35 AM DEBATE: Liver Transplantation is a Treatment For Portopulmonary Hypertension (CON)

Kelly Chin, MD, UT Southwestern Medical Center, Dallas, TX, USA

7:50 AM Panel Discussion

SUNRISE SYMPOSIUM 05: Making the Move: Accelerating Basic Science to Novel Clinical Trials in Transplant (510AC)

Primary Audience: BSTR

Secondary Audience: HF/HTX, LF/LTX, PATH, PHARM

Session Summary: Despite a desperate need for novel therapies to prevent or reverse chronic rejection, there has been a paucity of clinical trials in this area. This symposium will discuss barriers to interventional trials in transplant and their potential solutions.

Chairs: Laurie D. Snyder, MD and Simon Pecha, MD

7:00 AM Changing the Endgame: Surrogate Markers Instead of Clinical Endpoints?

Jamie L. Todd, MD, Duke University Medical Center, Durham, NC, USA

7:15 AM Q & A

7:20 AM Sharing the Love: Translating Pre-Clinical Discoveries and Borrowing from Other Therapeutic Areas to Transplantation

Patricia Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

7:35 AM Q & A

7:40 AM Maximizing Efficiency: Novel Clinical Trial Designs

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

7:55 AM Q & A

SUNRISE SYMPOSIUM 06: The Eternal Challenge: Difficult-to-Treat Organisms in Thoracic Transplantation (516BC)

Primary Audience: ID

Secondary Audiences: HF/HTX, LF/LTX, PHARM

Session Summary: Despite advances in surgical technique and immunosuppressive management, infection remains a significant cause of morbidity among thoracic transplant recipients. Multidrug-resistant Gram-negative bacteria and nontuberculous mycobacteria are challenging to treat due to a limited antimicrobial armamentarium and toxicities. The global spread of newer multidrug-resistant pathogens such as Candida auris poses challenges for thoracic transplant candidates and recipients.

Chairs: Shalika Katugaha, MD and Erik Verschuuren, MD, PhD

7:00 AM Expanding the Armamentarium: New Drugs and Novel Therapies for the Treatment of Multidrug-Resistant Gram-Negatives

Stephanie Pouch, MD, Emory University, Atlanta, GA, USA

7:15 AM Q & A

7:20 AM The New Fungal Threat: Candida auris Infections in Thoracic Transplant Candidates and Recipients

Shirish Huprikar, MD, Mount Sinai, New York, NY, USA

7:35 AM Q & A

7:40 AM Draining the Abscess: Inside Mycobacterium abscessus

Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

7:55 AM Q & A

SUNRISE SYMPOSIUM 07: DSAs and AMR: When and How to Treat (510BD)

Primary Audience: NHSAH

Secondary Audiences: HF/HTX, PEDS, PHARM

Session Summary: This session will provide guidance on when and how to treat the highly sensitized peri-operative candidate for transplant. Speakers will discuss treatment of donor specific antibodies identified in the post-transplant phase, and the treatment plan for recipients who develop antibody mediated rejection.

Chairs: Kevin C. Carney, MSN, CRNP, CCTC and Emilie Jean St. Michel, MD

7:00 AM Peri-Operative Treatment of the Sensitized Candidate

Patricia P. Chang, MD, University of North Carolina, Chapel Hill, NC, USA

7:15 AM Post-Transplant DSAs: When and How to Treat

Angela W. Velleca, RN, BSN, CCTC, Cedars Sinai Heart Institute, Los Angeles, CA, USA

7:30 AM AMR in Pediatric and Adult Post-Transplant Recipients

Steven P. Ivulich, BPharm, The Alfred Hospital, Melbourne, Australia

7:45 AM Panel Discussion

SYMPOSIUM 11: The Good, the Bad, the Ugly: Individualized VAD Therapy (517A)

Primary Audience: MCS

Secondary Audiences: HF/HTX, NHSAH, PHARM

Session Summary: Tailoring treatments to individual patients has revolutionized other fields of medicine, but personalized therapies still need to gain attention in the left ventricle assist devices (LVADs) field. Even if LVADs are just few types, they are implanted in patients with different clinical and cultural characteristics. This symposium focuses on current disparities among LVAD patients and it investigates the importance of individualized therapies, titrated on sex, body mass, ethnicity and culture.

Chairs: Cally K. Ho, MD and Jaime A. Hernandez Montfort, MD MPH

8:15 AM Gender Matters Before, During and After LVAD Implantation

Silvia Mariani, MD, Hannover Medical School, Hannover, Germany

8:30 AM Asterix or Obelix? Don´t Forget Body Mass Index!

Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, USA

8:45 AM Social Environment: Essential But Underestimated

Alessandro Barbone, MD, Instituto Clinico Humanitas, Milan, Italy

9:00 AM Europe, North America and Australia: Brothers But Not Triplets in the VAD Family

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

9:15 AM VADs in Asia, Africa and South America: The Need for Local Standards

Erik Fung, MD, PhD, Prince of Wales Hospital, Hong Kong, China

9:30 AM The Complexity of a VAD Patient: How to Reach an Individualized Therapeutic Approach

Pascal N. Leprince, MD, PhD, La Pitie Salpetriere, Paris, France

9:45 AM Panel Discussion

SYMPOSIUM 12: When the Left Appears to be Normal and the Right Goes Wrong: HFpEF and Infiltrative Cardiomyopathies (210EF)

Primary Audience: HF/HTX

Secondary Audiences: PATH, PH, PHARM

Session Summary: This session focuses on heart failure with preserved ejection fraction, including etiologies and hemodynamics, and the utility of advanced imaging techniques in diagnosis. This session also will discuss infiltrative cardiomyopathies, particularly conditions that often present with RV involvement or right heart failure, including amyloidosis and sarcoidosis, The speakers will discuss how to manage the specific cardiomyopathy, and when to refer these patients for advanced HF therapies. A panel discussion with all speakers will conclude this session.

Chairs: Richard K. Cheng, MD and Bojan Vrtovec, MD, PhD

8:15 AM CASE PRESENTATION: A Challenging Case of Dyspnea in an Older Woman

Thomas Cascino, MD, MSc, University of Michigan, Ann Arbor, MI, USA

8:20 AM Pathophysiology and Hemodynamics of Heart Failure with Preserved Ejection Fraction

Sanjiv J. Shah, MD, Northwestern University, Chicago, IL, USA

8:35 AM Role of Imaging in Assessing HFpEF - Echocardiography, MRI, and PET: Is Ejection Fraction Overrated?

Jerry D. Estep, MD, Cleveland Clinic, Cleveland, OH, USA

8:50 AM HFpEF: Treatment Options in Different Clinical Settings

Maria Frigerio, MD, A.O. Niguarda Ca' Granda, Milan, Italy

9:05 AM CASE PRESENTATION: ATTR Amyloid Patient with Severe Restrictive Physiology/Right Heart Failure and Pulmonary Hypertension

Elsy V. Navas, MD, Cleveland Clinic Florida, Weston, FL, USA

9:10 AM Restrictive Physiology and Emerging Treatment Options in ATTR Amyloidosis

Natasha Altman, MD, University of Colorado, Aurora, CO, USA

9:25 AM CASE PRESENTATION: Right Heart Failure and Pulmonary Hypertension in Sarcoidosis

Stephen Pan, MD, NYU Langone Medical Center, New York, NY, USA

9:30 AM Quest for Quiescence: Treating RV Dysfunction, Pulmonary Hypertension, and Arrhythmias in Sarcoidosis

Maja Cikes, MD, PhD, University of Zagreb School of Medicine, Zagreb, Croatia

9:45 AM Panel Discussion

SYMPOSIUM 13: From PCD to CLAD: The Lifespan of a Lung Allograft (511)

Primary Audience: LF/LTX

Secondary Audiences: BSTR, ID, PATH, PEDS, PHARM

Session Summary: Lung allografts survive numerous damaging insults, with the recipient ultimately succumbing to chronic lung allograft dysfunction (CLAD). The initial insult occurs at the time of transplant surgery leading to primary graft dysfunction (PGD). Over months to years, cumulative damage to the allograft from PGD, rejection, infection, and antibody production results in irreversible CLAD. In this session, we will review mechanistic data regarding these critical events limiting lung allograft longevity.

Chairs: John Dark, MD and Allison Carroll, MD

8:15 AM Clinical Strategies for the Prevention of Primary Graft Dysfunction: What's New on the Horizon

Jason Christie, MD, University of Pennsylvania, Philadelphia, PA, USA

8:30 AM Primary Graft Dysfunction: Molecular Mechanisms

Ciara M. Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA

8:45 AM Novel Cellular Modulators of Allograft Inflammation and Injury

Daniel Chambers, MD, The Prince Charles Hospital, Brisbane, Australia

9:00 AM Infectious Triggers of Increased Inflammation

Andrew J. Fisher, PhD FRCP, Newcastle University, Newcastle Upon Tyne, United Kingdom

9:15 AM CLAD: What’s New in Terms of Clinical Risk?

Robin Vos, MD, PhD, University Hospitals Leuven, Leuven, Belgium

9:30 AM CLAD: Molecular Mechanisms

Vibha N. Lama, MD, MS, University of Michigan, Ann Arbor, MI, USA

9:45 AM Panel Discussion

SYMPOSIUM 14: Selection of Donors for Pediatric Heart and Lung Transplantation: Maximizing Use of a Limited Resource (510AC)

Primary Audience: PEDS

Secondary Audience: HF/HTX, LF/LTX, NHSAH

Session Summary: This session aims to report the current state of donor selection and management, discuss the factors that impact donor acceptance, highlight provider behaviors that may negatively impact donor utilization, discuss the positive and negative impacts of publicly reported outcome data, and discuss future strategies to optimize the utilization of potentially viable donor hearts and lungs.

Chairs: Justin Godown, MD and Ernestina Melicoff, MD

8:15 AM Donor Allocation Systems Across the Globe: How Can We Improve Use of Limited Resources?

Jens Boehmer, MD, The Queen Silvia Children's Hosp, Gothenburg, Sweden

8:30 AM Donor Selection Among Pediatric Heart Transplant Providers: Waste Not, Want Not

Anna Joong, MD, Lurie Children's Hospital, Chicago, IL, USA

8:45 AM Donor Selection Among Pediatric Lung Transplant Providers: Waste Not, Want Not

Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

9:00 AM Donor Assessment Scoring in Pediatric Heart Transplantation to Ensure the Optimal Use of Organs

Farhan Zafar, MD, Children's Hospital Medical Center, Cincinnati, OH, USA

9:15 AM Behavioral Economics: How Our Biases Impact Provider Decision-Making in Donor Selection

Gretchen Chapman, PhD, Carnegie Mellon University, Pittsburgh, PA, USA

9:30 AM Public Reporting of Transplant Outcomes: Does This Change Our Willingness to Take Organs?

Ryan Davies, MD, Children's Hospital, Dallas, TX, USA

9:45 AM Panel Discussion

SYMPOSIUM 15: Great Debates in MCS and Transplant Care (510BD)

Primary Audience: NHSAH

Secondary Audience: HF/HTX, LF/LTX, MCS, PEDS, PH, PHARM

Session Summary: Clinicians face daily challenges and debates in the care of our patients. Hot discussion topics among our teams and colleagues will include strategies around anticoagulation in MCS, device implantation or transplantation without social support, and decisions related to stopping life-sustaining treatments. This symposium will feature 3 debates from multidisciplinary clinicians on these burning topics.

Chairs: Gregory Macaluso, MD and Gro Sorensen, RN CCN

8:15 AM DEBATE: Every MCS Patient Needs Anticoagulation (PRO)

Nicola Robinson Smith, RN, Freeman Hospital, Newcastle upon Tyne, United Kingdom

8:30 AM DEBATE: Every MCS Patient Needs Anticoagulation (CON)

Sara Strout, PharmD, Johns Hopkins, Baltimore, MD, USA

8:45 AM DEBATE: We Can and Should Implant or Transplant without Social Support (PRO)

Sarah E. Schroeder, ACNP-BC, MSN, RN, Bryan Heart, Lincoln, NE, USA

9:00 AM DEBATE: We Can and Should Implant or Transplant without Social Support (CON)

Quincy Young, PhD, RPsych, St. Paul's Hospital, Vancouver, BC, Canada

9:15 AM DEBATE: The Final Decision to Turn Off the Pump Lies With The Patient (PRO)

Karen Meehan, MSN, University of Chicago, Chicago, IL, USA

9:30 AM DEBATE: The Final Decision to Turn Off the Pump Lies With The Patient (CON)

Shunichi Nakagawa, MD, Columbia University Medical Center, New York, NY, USA

9:45 AM Panel Discussion

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

10:00 AM – 10:30 AM

Coffee Break

10:30 AM - 12:15 PM

PLENARY SESSION (517A)

Primary Audience: ALL

Chairs: Lori West, MD, DPhil and Maryl R. Johnson, MD

10:30 AM Lifetime Achievement Award Recipient Lecture

James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL, USA

11:00 AM Mechanical Circulatory Support: Past, Present and Future

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

11:20 AM Translating Tissue Engineered Heart Repair

Wolfram H. Zimmermann, MD, Uiversity of Goettingen, Goettingen, Germany

11:40 AM Management of Lung Failure in 2040 - Artificial Lung or Regeneration?

Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada

12:00 PM Transplant Medicine in the Age of Machine Learning

Alvin Rajkomar, MD, UCSF Medical Center, San Francisco, CA, USA

12:30 PM – 2:00 PM

Lunch Break

SYMPOSIUM 16: Greasing the Wheels: Antiplatelet Therapy for LVADS (516BC)

Primary Audience: PHARM

Secondary Audiences: HF/HTX, MCS, NHSAH

Session Summary: Management of antiplatelet therapies in patients with or awaiting durable LVAD and/or heart transplant has become highly variable due to the absence of well-controlled clinical trials evaluating the risk vs. benefit ratio of these agents. The management of these agents can be very challenging in certain scenarios. This symposium will review the existing data and provide discussion on management of these agents. A panel discussion with all speakers will conclude this session.

Chairs: Ian B. Hollis, PharmD, BCPS and Meredith Brisco-Bacik, MD, MSCE, FACC

2:00 PM More Than Warfarin: Oral Antiplatelet Therapy for Primary Prevention of Thromboembolic Events

Andrew Mardis, PharmD, Prisma Health, Columbia, SC, USA

2:15 PM Putting Out the Fire: Antiplatelet Agents for the Acute Management of Pump Thrombosis

Phillip Weeks, PharmD, Memorial Hermann - Texas Medical Center, Houston, TX, USA

2:30 PM Down to the Nitty Gritty: Platelet Function-Guided Management of Antiplatelet Therapy

Marvin Slepian, MD, University of Arizona, Tucson, AZ, USA

2:45 PM Timing is Everything: Management of Dual Antiplatelet Therapy Before or After LVAD

Amanda Ingemi, PharmD, Sentara Norfolk General Hospital, Falls Church, VA, USA

3:00 PM DEBATE: Routine Use of Antiplatelet Agents Should Be Standard of Care for Durable LVADs (PRO)

Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

3:15 PM DEBATE: Routine Use of Antiplatelet Agents Should Be Standard of Care for Durable LVADs (CON)

Christopher Michaud, PharmD, Spectrum Health, Grand Rapids, MI, USA

3:30 PM Panel Discussion

SYMPOSIUM 17: Segmental and Subsegmental Disease in CTEPH: Misconception and Missed Opportunities (510AC)

Primary Audience: CTEPH

Secondary Audience: PH

Session Summary: This symposium will specifically focus on segmental and subsegmental disease in CTEPH. The management of segmental and subsegmental disease has evolved over the past decade. Pulmonary endarterectomy and balloon pulmonary angioplasty have been shown to be excellent therapeutic options for these patients. However, both options have not yet been widely adopted due to technical challenges.

Chairs: Joanna Pepke-Zaba, MD and Isabelle Opitz, MD

2:00 PM Prevalence of Segmental/Subsegmental Disease in CTEPH: How To Overcome a Missed Diagnosis?

Kim M. Kerr, MD, UCSD Medical Center, La Jolla, CA, USA

2:15 PM Q & A

2:20 PM What is the Most Reliable Way to Identify Segmental/Subsegmental Disease: Selective Pulmonary Angiography, CT, or MRI?

Micheal McInnis, MD, University of Toronto, Toronto, ON, Canada

2:35 PM Q & A

2:40 PM Surgical Techniques in Segmental CTEPH: Tips and Tricks

Michael M. Madani, MD, UCSD Medical Center, La Jolla, CA, USA

2:55 PM Q & A

3:00 PM BPA Techniques in Segmental CTEPH: Tips and Tricks

Aiko Ogawa, MD, Okayama Medical Center, Okayama, Japan

3:15 PM Q & A

3:20 PM Global Perspective on Management of Segmental CTEPH: Medical Therapy, BPA, PEA

Julius Punnen, MD, Narayana Health, Bangalore, Karnataka, India

3:35 PM Q & A

3:45 PM – 4:15 PM

Coffee Break

SYMPOSIUM 18: Everybody Else is Doing It So Why Can't We? Mechanical Circulatory Support in Adults with Congenital Heart Disease (517A)

Primary Audience: MCS

Secondary Audience: HF/HTX, PEDS, PH

Session Summary: Durable mechanical circulatory support (MCS) has revolutionized care for end-stage heart failure patients, however remains rarely used in adults with congenital heart disease (ACHD). This session will present the most recent data on MCS use in ACHD generally including patient and device selection and post MCS outcomes. The session will include a debate on the optimal MCS strategy to be used in the most complex patient group: Fontan-palliated single ventricle patients. A panel discussion with all speakers will conclude this session.

Chairs: David Crossland, MRCP and Angela Lorts, MD

4:15 PM How Soon is Now? Timing of Referral for Advanced Heart Failure Care in Adult Congenital Heart Disease

Lucy Roche, MB ChB, University of Toronto, Toronto, ON, Canada

4:35 PM Realizing the Promise of VAD Technology in Adult Congenital Heart Disease

Ari M. Cedars, MD, Baylor University Medical Center, Dallas, TX, USA

4:55 PM DEBATE: Fontan Patients Should Get Cavopulmonary Support for Bridge to Transplant (PRO)

Stephanie Fuller, MD, University of Pennsylvania, Philadelphia, PA, USA

5:10 PM DEBATE: Fontan Patients Should Get Cavopulmonary Support for Bridge to Transplant (CON)

Bart Meyns, MD, PhD, UZ Leuven, Leuven, Belgium

5:25 PM The ACTION Network: Acceleration Group Learning in Congenital MCS

Kurt Schumacher, MD, University of Michigan, Ann Arbor, MI, USA

5:45 PM Panel Discussion

SYMPOSIUM 19: Controversial Debates in Valvular and Structural Heart Disease and Heart Failure (210EF)

Primary Audience: HF/HTX

Secondary Audience: MCS, PEDS

Session Summary: Despite advances in the treatment of valvular heart disease and the emergence of TAVR and MitraClip, questions remain regarding patient selection and therapeutic options for left ventricular dysfunction and right-sided valves. This session will include rapid fire debates on challenging questions in the field, including valve repair versus advanced HF therapies in severe LV dysfunction, whether LV remodeling techniques have a role in the modern era, and valve options for the right heart. A panel discussion with all speakers will conclude this session.

Chairs: Luanda P. Grazette, MD and Richard C. Daly, MD

4:15 PM DEBATE: Device-Directed Left Ventricular Remodeling Improves Patient Outcomes (PRO)

Emma Birks, MD, PhD, University of Louisville, KY, USA

4:30 PM DEBATE: Device-Directed Left Ventricular Remodeling Improves Patient Outcomes (CON)

Steven SL Tsui, MD, FRCS, Papworth Hosp NHS Trust, Cambridge, United Kingdom

4:45 PM DEBATE: Remembering the Right Heart: Percutaneous Options are Ideal for the Tricuspid and Pulmonic Positions (PRO)

Valluvan Jeevanandam, MD, University of Chicago Medical Center, Chicago, IL, USA

5:00 PM DEBATE: Remembering the Right Heart: Percutaneous Options are Ideal for the Tricuspid and Pulmonic Positions (CON)

Renata Shih, MD, University of Florida, Gainesville, FL, USA

5:15 PM DEBATE: Valve Repair/Replacement is Always a Good Option Regardless of LV Function (PRO)

JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

5:30 PM DEBATE: Valve Repair/Replacement is Always a Good Option Regardless of LV Function (CON)

Alejandro M. F. Bertolotti, Sr., MD, University Hospital Favaloro Foundation, Buenos Aires, Argentina

5:45 PM Panel Discussion

SYMPOSIUM 20: HCV State of the Art: How Do We DO This? An ISHLT HCV Consensus Conference (516BC)

Primary Audience: ID

Secondary Audiences: HF/HTX, LF/LTX, PHARM

Session Summary: This symposium will offer practical insights from the recent ISHLT HCV consensus conference and will discuss recommendations regarding use of HCV+ organs for cardiothoracic (CT) transplant. This includes details regarding direct acting antiviral therapy for HCV, with a focus on drug interactions, financial and waitlist time implications, summarize early results from use of HCV+ donors in CT transplant and management strategies regarding recipient and donor selection, and treatment of HCV.

Chairs: Emily A. Blumberg, MD and Haifa Lyster, MSc

4:15 PM Direct Acting Antivirals for HCV: A Whole New World!

Laura Lourenco, PharmD, University of Chicago Medicine, Chicago, IL, USA

4:30 PM Q & A

4:35 PM HCV Treatment Paradigms: Early Results from Cardiothoracic Transplantation and Consensus Recommendations

Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA

4:50 PM Q & A

4:55 PM Donor Profiles and Recipient Selection Criteria when Considering HCV-Infected Donors

Cameron Wolfe, MD, Duke University, Durham, NC, USA

5:10 PM Q & A

5:15 PM Approaches to Donor-Derived HCV Infection: The Practical Applications of Pre-Emptive and Delayed Therapy

Ann E. Woolley, MD, MPH, Brigham and Women's Hospital, Boston, MA, USA

5:30 PM Q & A

5:35 PM Financial and Waitlist Time Implications from the Use of HCV+ Organs

Mandeep R. Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital, Boston, MA, USA

5:50 PM Q & A

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

6:00 PM – 7:15 PM

POSTER SESSION 02

Information on ISHLT2020 Poster Sessions will be available in January 2020

Friday, April 24, 2020

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 08: VAD Infection: What Are We Doing Wrong? (517A)

Primary Audience: MCS  
Secondary Audience: ID, NHSAH, PHARM  
  
Session Summary: This session will provide an overview of evidence-based approaches to diagnosis and management of LVAD infections. Individual speakers will add their own personal experience. Lectures will cover all aspects of non-VAD specific to VAD specific infection from the peri-operative period to months/years after implantation.  
  
Chairs: Keyur Shah, MD and Margaret M. Hannan, MD

|  |  |
| --- | --- |
| 7:00 AM | Drive-Line Infection: Perils and Comprehensive Mitigation Strategies Michael Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany |
| 7:15 AM | Internal Pump Components Infection Nir Uriel, MD, New York-Presbyterian Hospital, New York, NY, USA |
| 7:30 AM | LVAD Exchange or Heart Transplantation in Intractable Pump Infection? Marian Urban, MD, PhD, University of Nebraska Medical Center, Omaha, NE, USA |
| 7:45 AM | Panel Discussion |

SUNRISE SYMPOSIUM 09: Rewinding the Antibodies: Managing Highly Sensitized Patients Pre-Transplant (210EF)

Primary Audience: PHARM

Secondary Audience: HF/HTX, LF/LTX, NHSAH, PEDS

Session Summary: This symposium will provide an overview of important topics regarding antibodies and desensitization for thoracic transplant recipients. Topics reviewed will include immunology, strategies for desensitization, and sensitization considerations with regard to prioritization and allocation of organs.

Chairs: Amy Kiskaddon, PharmD and Adam Cochrane, MD

7:00 AM Blues Brothers: HLA and Non-HLA Antibodies

Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

7:15 AM Q & A

7:20 AM Ghostbusters: Strategies for Desensitization

Fay S. Burrows, PharmD, BCPS, St. Vincent's Hospital, Sydney, Australia

7:35 AM Q & A

7:40 AM Stand By Me: Organ Allocation and Sensitized Patients

Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

7:55 AM Q & A

SUNRISE SYMPOSIUM 10: Advances in the Microbiome: The Secret World Inside Us (510BD)

Primary Audience: BSTR

Secondary Audience: HF/HTX, ID LF/LTX, MCS

Session Summary: It is now understood that the human body is home to a multitude of niche environments, each with their own unique microbiome, which appears to have an important symbiotic role with the host and modulates functioning of the associated organ system. The most researched of these is the gut microbiome. Although, our understanding of this symbiotic relationship has stemmed from gut-based research, it developed to include the reciprocal relationships between the gut and other organs including the heart and lung.

Chairs: W. H. Wilson Tang, MD and Nancy Law, DO, MPH

7:00 AM The Gut Microbiome as a Modulator in Transplant

Steven Greenway, MD, Alberta Children's Hospital, Calgary, AB, Canada

7:15 AM Q & A

7:20 AM The Microbiome Changes of Heart Failure, Heart Transplant and MCS

Melana Yuzefpolskaya, MD, Columbia University, New York, NY, USA

7:35 AM Q & A

7:40 AM The Microbiome After Lung Transplantation and Effects on CLAD

Alicia B. Mitchell, B.Med.Sci, Sydney Medical School/University of Sydney, Sydney, Australia

7:55 AM Q & A

SUNRISE SYMPOSIUM 11: Challenging CTEPH Surgical Cases in the BPA Era (210AB)

Primary Audience: CTEPH

Secondary Audience: PH

Session Summary: BPA is becoming a new standard of treatment for inoperable CTEPH patients as it achieved satisfactory early and mid-term outcomes. Hence, it appears a grey zone for operable patients with distal disease whose surgery remains challenging and BPA seems possible. The aim of the session is to present surgical results of distal pulmonary endarterectomy (splenectomy, chronic emboli from catheter, blood disorders) and debate to know what is the best treatment of this challenging subset of patients.

Chairs: Marc de Perrot, MD and Andrea D'Armini, MD

7:00 AM Case Presentation: Pulmonary Endarterectomy in Catheter-Induced CTEPH Patients

Andrea M. D'Armini, MD, University of Pavia School of Medicine, Pavia, Italy

7:05 AM Case Presentation: Pulmonary Endarterectomy in Blood Disorders Patients

David P. Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom

7:10 AM Case Presentation: Pulmonary Endarterectomy in Splenectomised Patients

Marc De Perrot, MD, Toronto General Hospital, Toronto, ON, Canada

7:15 AM DEBATE: CTEPH in High-Risk Patients is Better Managed Using BPA Rather Than Undergoing Pulmonary Endarterectomy (PRO)

Hiromi Matsubara, MD, PhD, Nat’l Hosp Org Okayama Med Ctr, Okayama, Japan

7:30 AM DEBATE: CTEPH in High-Risk Patients is Better Managed Using BPA Rather Than Undergoing Pulmonary Endarterectomy (CON)

Elie Fadel, MD, Hosp Marie Lannelongue, Le Plessis Robinson, France

7:45 AM Panel Discussion

SUNRISE SYMPOSIUM 12: Cardiac Allograft Injury: It's More Than Just Rejection (510AC)

Primary Audience: PATH

Secondary Audience: BSTR, HF/HTX

Session Summary: Cardiac allograft dysfunction (CAD) reflects myocardial injury (MI). Previously attributed to acute cellular rejection and infection, the current etiology is multifactorial. New diagnostic modalities are directed at detection and enumeration of MI. This symposium will discuss CAD as a consequence of MI. Clinicians and pathologists will be aware of causes of injury and how diagnostic modalities address them. The symposium will unite clinicians and pathologists to discuss emerging modalities.

Chairs: Martin Goddard, MD and Brandon T. Larsen, MD, PhD

7:00 AM Histopathology of Allograft Injury: A Temporal Paradigm

Gerald J. Berry, MD, Stanford University, Stanford, CA, USA

7:15 AM Q & A

7:20 AM Allograft Dysfunction: A Clinician's Approach to a Common Dilemma

Christopher S. Hayward, MD, St. Vincent's Hospital, Sydney, Australia

7:35 AM Q & A

7:40 AM Integration of Information Overload: The Role of the Pathologist

Ornella Leone, MD, University of Bologna, Bologna, Italy

7:55 AM Q & A

SUNRISE SYMPOSIUM 13: Let's Talk about Sex, Baby! Intimacy in MCS and Transplant Patients (511)

Primary Audience: NHSAH

Secondary Audience: HF/HTX, LF/LTX, ID, MCS, PEDS, PH, PHARM

Session Summary: This multidisciplinary symposium focuses on issues specific to sexual intimacy and fertility in patients receiving device therapies, cardiac or lung transplantation. Topics will include: impact of heart failure medication on sexual potency, ethical issues and decision making around unplanned pregnancies, sexually transmitted infections, and fertility treatment, and supporting patients with device therapies around intimacy concerns.

Chairs: Annemarie Kaan, MCN, RN and Pamela Combs, PhD RN

7:00 AM I Can’t Get No Satisfaction: Pharmacological Considerations

Nathan Verlinden, PharmD, Allegheny General Hospital, Pittsburgh, PA, USA

7:15 AM Q & A

7:20 AM Papa Don't Preach: STI, Fertility and Pregnancy Dilemmas

Vasiliki Gerovasili, MD, Queen Elizabeth Hospital, Oxford, UK

7:35 AM Q & A

7:40 AM Rock With You: Sexual Intimacy and Device-Therapy in MCS Patients

Melissa Sanchez, BSc, PGDip, MSc, DClinPSy, Royal Brompton Hospital, Harefield, United Kingdom

7:55 AM Q & A

SUNRISE SYMPOSIUM 14: Pediatric Pulmonary Hypertension: Management of Advanced Disease and Thoracic Transplant Referral (516BC)

Primary Audience: PEDS

Secondary Audience: CTEPH, LF/LTX, PH, PHARM

Session Summary: This session will bring together experts on pediatric pulmonary hypertension for a discussion that is much needed regarding the treatment of advanced pulmonary vascular diseases in children. In addition to medical management, discussions will include surgical management and referral for thoracic transplantation in refractory cases.

Chairs: Don Hayes, MD and Melinda Solomon, MD

7:00 AM How Many Drugs are Enough to Treat Severe Pediatric Pulmonary Hypertension?

Nidhy Varghese, MD, Baylor College of Medicine, Houston, TX, USA

7:15 AM Q & A

7:20 AM Surgical Management of Severe Pulmonary Hypertension in Children Prior To or Instead Of Lung Transplantation?

Pirooz Eghtesady, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA

7:35 AM Q & A

7:40 AM When to Refer a Child with Pulmonary Hypertension for Thoracic Transplant

Brigette Willemse, MD, University Medical Center Groningen, Groningen, Netherlands

7:55 AM Q & A

8:15 AM – 10:00 AM

SYMPOSIUM 21: Joint ISHLT/PVRI Symposium: Of Mice and Men (210AB)

Primary Audience: PH

Secondary Audience: BSTR, CTEPH, LF/LTX, PEDS

Session Summary: In collaboration with the Pulmonary Vascular Research Institute (PVRI), the ISHLT is pleased to offer this joint symposium. The management of PAH has considerably evolved in the past years; however, the development of disease-modifying therapies faces challenges witnessed by a high number of negative Phase II trials. Do we make the right choice of agents? Should we change our RCT paradigm? How do we measure success and how does this translate in real-life management? These are some key questions the symposium will try to answer with world-leading experts who will discuss how the future will look like.

Chairs: Paul Corris, MB FRCP and Trevor Williams, MD

8:15 AM Journey to the Center of the Cell: New Pathways and Beyond

Sebastien Bonnet, PhD, FAHA. Pulmonary Hypertension Research Group, Quebec, QC, Canada

8:40 AM Intolerable Cruelty or Why Phase II Trials Failed

Olivier Sitbon, MD. Hopital Universitaire de Bicêtre, Paris Sud, France

9:05 AM Facing the Void: How Do We Define Success in PAH?

Jean-Luc Vachiery, MD. Erasme University Hospital, Brussels, Belgium

9:25 AM The Full Monty: Tools and Tricks for a Better Management

Raymond L. Benza, MD. Allegheny General Hospital, Pittsburgh, PA, USA

9:50 AM Panel Discussion

SYMPOSIUM 22: A Balancing Act: Innate Mechanisms of Injury and Immunomodulation in Transplantation (510BD)

Primary Audience: BSTR

Secondary Audience: HF/HTX, LF/LTX, PATH, PHARM

Session Summary: Transplant immunology is a rapidly advancing field. This session aims to challenge existing paradigms regarding how the innate immune system and its effector cells are helpful or harmful to thoracic allografts. Identifying similarities and differences between heart and lung transplant immunology may help advance understanding of the immunobiology of both organs. The primary goal of this session is to enrich understanding of allograft immune responses with a focus on targets for interventions.

Chairs: Christian Heim, MD and Ciara M. Shaver, MD PhD

8:15 AM Setting the Stage

Christian Heim, MD, University of Erlangen, Erlangen, Germany

8:20 AM Cellular Death: The Kickoff

Mingyao Liu, MD, Toronto General Hospital, Toronto, ON, Canada

8:35 AM Q & A

8:40 AM Mitochondria: A Game Changer

Andrew E. Gelman, PhD, Washington University School of Medicine, St. Louis, MO, USA

8:55 AM Q & A

9:00 AM Endothelium and Epithelium: Ground Zero

Christine Falk, PhD, Hannover Medical School, Hannover, Germany

9:15 AM Q & A

9:20 AM Complement: Defending Cell Integrity

Hrishikesh S. Kulkarni, MD, Washington University in St Louis, Saint Louis, MO, USA

9:35 AM Q & A

9:40 AM Therapeutic Targets for Innate Immune Manipulation: The Comeback

Karl B. Lemstrom, MD, PhD, Helsinki University, Helsinki, Finland

9:55 AM Q & A

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

10:30 AM – 12:15 PM

SYMPOSIUM 23: Short-Term Mechanical Circulatory Support in Bridging the Gap Between Recovery and Transplant (517A)

Primary Audience: MCS

Secondary Audience: CTEPH, HF/HTX, PEDS, PH

Session Summary: The symposium will review all short-term circulatory support devices and their pros and cons. We will discuss which patients are best suited for short-term support, which would do better with durable support, and who should not be supported at all. We will discuss how to manage the acute heart failure patient; specifically, which patients will recover and which should be transitioned to durable support or transplant. Finally, we will review the new heart allocation system in the US and its impact on decision making around support strategies.

Chairs: Carmelo A. Milano, MD and Jens Garbade, MD, PhD

10:30 AM Percutaneous Management of the Acute Heart Failure Patient

David Schibilsky, MD, University of Freiburg, Freiburg, Germany

10:45 AM Surgical Management of the Acute Heart Failure Patient, Temporary vs Durable Support

Julia Riebandt, MD, University of Vienna, Vienna, Austria

11:00 AM Will This Heart Beat Again? Who Will Recover and Who to Transplant

Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

11:15 AM Novel Strategies for Extended Support for Pediatric and Adult Patients with 'Short-Term' Mechanical Circulatory Support

Iki Adachi, MD, Texas Children´s Hospital, Houston, TX, USA

11:30 AM DEBATE: Short-Term MCS is the Best Strategy for Bridge to Heart Transplant (PRO)

Lauren B. Cooper, MD, MHS, Inova Heart and Vascular Institute, Fairfax, VA, USA

11:45 AM DEBATE: Short-Term MCS is the Best Strategy for Bridge to Heart Transplant (CON)

Jeffrey J. Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, USA

12:00 PM Panel Discussion

SYMPOSIUM 24: Joint ISHLT/TTS Symposium: Meeting Ethical Challenges in Transplantation Through Global Partnership (210EF)

Primary Audience: ALL

Session Summary: In collaboration with The Transplantation Society (TTS), this joint symposium will address the challenges of organ transplantation across borders. Country disparities in the access to transplantation lead to ethical dilemmas when organs, donors or recipients cross the borders. Good collaborative experiences as well as the challenges of transplant tourism or organ traffic will be discussed. Experiences on the rise of transplant programs in developing countries will be shared. Society policies regarding transplantation in China be will be discussed.

Chairs: Are M. Holm, MD, PhD and Nancy Ascher, MD

10:30 AM Cultural and Religious Implications in the Donation and Transplant Process

Marta Farrero, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

10:45 AM Transplantation Across International Borders: The Ethical Challenges

Nancy Ascher, MD, UCSF Medical Center, San Francisco, CA, USA

11:00 AM Established International Collaborations in Organ Sharing: Benefits and Challenges

Are M. Holm, MD, PhD, Oslo University Hospital, Oslo, Norway

11:15 AM Transplant Tourism: Recipients Crossing Borders

Komarakshi Balakrishnan, MD, Fortis Malar Hospital, Chennai, India

11:30 AM Partnerships for Establishing Deceased Donor Transplant Programs in Emerging Countries

Richard Allen, MBBS, University of Sydney, Sydney, Australia

11:45 AM Organ Transplantation in China

Jeremy Chapman, MD, University of Sydney, Sydney, Australia

12:00 PM Panel Discussion

SYMPOSIUM 25: ECMO and Lung Failure from Recovery to Transplant (511)

Primary Audience: LF/LTX

Secondary Audience: MCS, PEDS, PH

Session Summary: There is continued push from pulmonary and critical care teams to bridge sick patients to lung transplant with mechanical support. For most centers these patients pose a prohibitive risk due to poor 1-year survival, however, select programs are able to show equipoise between the mechanical support population and their standard transplant patients. This session will discuss best practices in respiratory ECMO as well as who, when, and how to bridge to lung transplant.

Chairs: Sandeep Attawar, MD and Jasleen Kukreja, MD, MPH

10:30 AM Building a Successful Bridge to Transplant Program: Pitfalls and Traps

Nathalie Roy, MD, Boston Children's Hospital, Boston, MA, USA

10:45 AM The Expanding Pool of ECMO Programs: Patient Selection Criteria and Ethical Considerations

Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

11:05 AM Successfully Transitioning from Pre-Operative to Intra-Operative to Post-Operative Mechanical Support

Mani A. Daneshmand, MD, Emory University, Atlanta, GA, USA

11:20 AM DEBATE: We Should Routinely Use EVLP for Marginal Organs (PRO)

Marcelo Cypel, MD, Toronto General Hospital, Toronto, ON, Canada

11:35 AM DEBATE: We Should Routinely Use EVLP for Marginal Organs (CON)

Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria

11:50 AM Debate Rebuttal (PRO)

Marcelo Cypel, MD, Toronto General Hospital, Toronto, ON, Canada

11:55 AM Debate Rebuttal (CON)

Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria

12:00 PM Panel Discussion

SYMPOSIUM 26: CMV: Great Debates on Prevention and Management Controversies (519AC)

Primary Audience: ID

Secondary Audience: HF/HTX, LF/LTX, PEDS, PHARM

Session Summary: Despite advances in diagnostics and prevention strategies, cytomegalovirus (CMV) infection continues to be a significant management challenge in thoracic organ transplantation. This session involves two pro and con debates and a lecture related to 3 controversial issues: 1) the duration of universal anti-viral prophylaxis, 2) the use of CMV-specific immune monitoring assays as adjuncts to viral load testing, and 3) approaches to the management of resistant or recurrent CMV.

Chairs: Michael Ison, MD and Lara Danziger-Isakov, MD, MPH

10:30 AM DEBATE: Universal CMV Prophylaxis Should Be Short Or Not Used At All (PRO)

Nicolas Mueller, MD, University of Zurich, Zurich, Switzerland

10:45 AM DEBATE: Universal CMV Prophylaxis Should Be Short Or Not Used At All (CON)

Emily A. Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

11:00 AM Debate Rebuttal (PRO)

Nicolas Mueller, MD, University of Zurich, Zurich, Switzerland

11:05 AM Debate Rebuttal (CON)

Emily A. Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

11:10 AM DEBATE: CMV-Specific Immune Monitoring Assays Are Ready For Prime Time! (PRO)

Laurie D. Snyder, MD, Duke University Med Ctr, Durham, NC, USA

11:25 AM DEBATE: CMV-Specific Immune Monitoring Assays Are Ready For Prime Time! (CON)

Camille Kotton, MD, Mass General Hospital, Boston, MA, USA

11:40 AM Debate Rebuttal (PRO)

Laurie D. Snyder, MD, Duke University Med Ctr, Durham, NC, USA

11:45 AM Debate Rebuttal (CON)

Camille Kotton, MD, Mass General Hospital, Boston, MA, USA

11:50 AM Resistance, Toxicities, and More: A Case-Based Approach to the Management of CMV in Lung Transplant Recipients

Catherine Burton, MD, University of Alberta, Edmonton, AB, Canada

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

2:00 PM – 3:45 PM

SYMPOSIUM 27: Joint ISHLT/AST Symposium: Challenges in Heart/Kidney Transplantation (210EF)

Primary Audience: HF/HTX

Secondary Audience: BSTR, PATH, PEDS, PHARM

Session Summary: In collaboration with the American Society of Transplantation (AST), this joint symposium will provide an overview of the pathophysiological basis of cardiorenal syndrome and treatment strategies, and indicators of irreversible kidney disease that lead to dual organ transplantation. Contrasting views from cardiology and nephrology regarding treatment of sensitized candidates and graft monitoring after dual transplantation will be discussed, as will ethical concerns surrounding dual organ transplantation and various allocation strategies. A panel discussion with all speakers will conclude this session.

Chairs: Areas Aliabadi-Zuckermann, MD and Darshana Dadhania, MD

2:00 PM The Pathophysiology of Cardio-Renal Disease Leading to End Organ Failure

Juan Ivey-Miranda, MD, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico

2:15 PM Interdisciplinary Management Strategies for Cardio-Renal Syndrome: Tools in Our Arsenal

Jeffrey M. Testani, MD, MTR, Yale University, New Haven, CT, USA

2:30PM Reversible or Irreversible Kidney Damage: How do I Know? Indications for Heart-Kidney Transplantation

Richard Formica, MD, Yale School of Medicine, New Haven, CT, USA

2:45 PM Sensitization in Heart-Kidney Transplantation

Darshana Dadhania, MD, Weill Cornell Medicine, New York, NY, USA

3:00PM Partners for Life: Monitoring and Caring for the Heart and Kidney Allografts

Arezu Aliabadi-Zuckermann, MD, Medical University of Vienna, Vienna, Austria

3:15 PM The Ethics of Dual Organ Transplantation: Evaluating Fairness in Organ Allocation

Jayme Locke, MD, MPH, University of Alabama at Birmingham, Birmingham, AL, USA

3:30 PM Panel Discussion

SYMPOSIUM 28: Lean On Me: Mechanical Support of the Right Ventricle in Pulmonary Hypertension (210AB)

Primary Audience: PH

Secondary Audience: CTEPH, HF/HTX, LF/LTX, MCS, PEDS

Session Summary: This session will focus on the role of mechanical circulatory support (ventricular assist devices, impeller devices, extracorporeal membranous oxygenation devices, etc) in the management of patients with advanced pulmonary hypertension with severe and complex heart failure physiology.

Chairs: Arun Jose, MD and Maria G. Crespo-Leiro, MD

2:00 PM Knowing When to Bail: Timing and Candidacy in MCS for End Stage Pulmonary Hypertension

Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA

2:15 PM Q & A

2:20 PM Tickle Me ECMO: What is the Best Configuration to Support the Failing Right Ventricle?

Sonja Bartolome, MD, UT Southwestern, Dallas, TX, USA

2:35 PM Q & A

2:40 PM DEBATE: ECMO Should Be Routine Perioperatively for PAH Patients Undergoing Transplant (PRO)

David McGiffin, MD, Alfred Institute, Melbourne, Australia

2:55 PM DEBATE: ECMO Should Be Routine Perioperatively for PAH Patients Undergoing Transplant (CON)

Christopher King, MD, Inova Fairfax Hospital, Falls Church, VA, USA

3:10 PM Debate Rebuttal (PRO)

David McGiffin, MD, The Alfred Hospital, Melbourne, Australia

3:15 PM Debate Rebuttal (CON)

Christopher King, MD, Inova Fairfax Hospital, Falls Church, VA, USA

3:20 PM Future of MCS in Management of RV Failure: Will it be Destination Therapy for Patients with PAH?

Olaf Mercier, MD, Paris-Sud University, Paris, France

3:35 PM Q & A

SYMPOSIUM 29: Shaping the Future of Thoracic Transplant Pathology: Multiplex, Multidisciplinary and Multimodality (510AC)

Primary Audience: PATH

Secondary Audience: BSTR, HF/HTX, LF/LTX

Session Summary: Ancillary techniques are set to refine, rather than replace, histopathologic diagnosis in transplant pathology, including expression profiling, miRNA, cfDNA, multiplex immunohistochemistry, image analysis, integration with radiology, and integration of complex data using algorithms (including artificial intelligence processing). The aim of this symposium is to provide an overview of these techniques, and to describe their role in modern transplant pathology practice, including both lung and heart transplantation.

Chairs: Jan H. von der Thüsen, MD and Fiorella Calabrese, MD

2:00 PM Immunohistochemistry, Special Stains and Automated Image Analysis in Post-Transplant Follow-Up Cardiac Biopsies

Gregory A. Fishbein, MD, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA

2:15 PM Immunohistochemistry, Special Stains and Automated Image Analysis in Post-Transplant Follow-Up Transbronchial Biopsies

Anja C. Roden, MD, Mayo Clinic, Rochester, MN, USA

2:30 PM MicroRNA Signatures and Exosomes in Cardiac Biopsies and Detection of Allograft Rejection

Marny Fedrigo, MD, University of Padua, Padua, Italy

2:45 PM Expression Profiling in Paraffin Material: A New Level of Understanding in Pathology

Benjamin Adam, MD, University of Alberta, Edmonton, AB, Canada

3:00 PM Correlation of Histology with (Micro)CT Images in CLAD: A Reciprocal Relationship

Stijn E. Verleden, PhD, KU Leuven, Leuven, Belgium

3:15 PM Making Sense of Big Data: Integration of Complex Data Using Algorithms

Alexandre Loupy, MD, Necker Hospital, Universite Paris Descartes, Paris, France

3:30 PM Panel Discussion

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

4:15 PM – 6:00 PM

SYMPOSIUM 30: When a Single Ventricle Support is Not Enough! (517A)

Primary Audience: MCS

Secondary Audience: CTEPH, HF/HTX, PEDS, PH

Session Summary: Biventricular failure is associated with high in-hospital mortality. The aim of this session is to explore the clinical utility of extra- and intracorporeal as well as percutaneous MCS for patients persisting biventricular failure. In this session the currently available devices for treating shock and heart failure and a look ahead within this developing field, including new devices and novel indications for established technology should be presented.

Chairs: Yaron Barac, MD and Emily K. Granger, MBBS

4:15 PM Defining Biventricular Heart Failure

Cesar I. Guerrero-Miranda, MD, Baylor University Medical Center, Dallas, TX, USA

4:30 PM Variety of Temporary Biventricular Support

Jamila Kremer, MD. University Hospital Heidelberg, Heidelberg, Germany

4:45 PM When Durable LVAD Alone is Not Enough: Short-Term Right Ventricular Mechanical Support in LVAD Patients

Sarah E. Scheuer, MD, St Vincent's Hospital, Sydney, Paddington, Australia

5:00 PM Paracorporeal Devices Still Exist: Continuous Flow VADs in Combination with Paracorporeal Devices

Jan D. Schmitto, MD, PhD, MBA, FCCP, FRCS, Hannover Medical School, Hannover, Germany

5:15 PM Which Device in Which Configuration for Biventricular Support: BiVAD vs Total Artificial Heart? How, Which and When?

Ivan Knezevic, MD, Univ Clinical Centre, Ljubljana, Slovenia

5:30 PM Do It Both Ways: BiVAD vs. Bivad in a TAH Configuration

Evgenij V. Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany

5:45 PM Panel Discussion

SYMPOSIUM 31: Global Perspectives on Decreasing Waitlist Mortality: Expanded Donors and Prioritized Candidates (210EF)

Primary Audience: HF/HTX

Secondary Audience: ID, MCS, PEDS

Chairs: Kiran K. Khush, MD, MAS and D. Eric Steidley, MD

4:15 PM The New Normal: Decreasing Waitlist Mortality and Increasing Transplant Rates from Donors with High Risk Features

Ricardo La Hoz, MD, University of Texas Southwestern, Dallas, TX, USA

4:30 PM Leveling the Playing Field: Decreasing Waitlist Mortality by Prioritizing Sensitized Patients in Canada

Kim Anderson, MD, University of Toronto, Toronto, ON, Canada

4:45 PM Just Because We Can, Doesn’t Mean We Should: Use of Status Modifying Therapies in Waitlist Urgency

Maria G. Crespo-Lairo, MD, Hosiptal Universitario A Coruna, La Coruna, Spain

5:00 PM More Opportunities: Evolving Practices Including Use of DCD and Advanced Age Donors

Kumud K. Dhital, BMBCh, FRCS-CTh, FRACS, PhD, Alfred Hospital, Melbourne, Australia

5:15 PM Getting Warmer: Expanding the Donor Pool with Use of Ex-Vivo Perfusion

Abbas Ardehali, MD, UCLA School of Medicine, Los Angeles, CA, USA

5:30 PM How We Got Here: Reflections on the Evolving OPTN Allocation System

Maryl R. Johnson, MD, University of Wisconsin, Madison, WI, USA

5:45 PM Panel Discussion

SYMPOSIUM 32: Challenges in Patient and Device Selection in Pediatric Heart Failure and Mechanical Circulatory Support (516BC)

Primary Audience: PEDS

Secondary Audience: HF/HTX, MCS, NHSAH

Session Summary: This symposium will explore the complexity of patient and device selection in pediatric MCS through 3 case-based debates, each highlighting a clinical scenario for which there is currently no standard approach. The session will present competing views on the risks and benefits of various management approaches to 3 distinct pediatric advanced heart failure populations.

Chairs: Aamir Jeewa, MD and Danielle S. Burstein, MD

4:15 PM DEBATE: All Neonates with DCM and Decompensated Heart Failure Should Receive a VAD as a Bridge to Transplant (PRO)

Joshua Friedland-Little, MD, Seattle Children's Hospital, Seattle, WA, USA

4:30 PM DEBATE: All Neonates with DCM and Decompensated Heart Failure Should Receive a VAD as a Bridge to Transplant (CON)

Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom

4:45 PM DEBATE: All Patients with Fulminant Myocarditis Failing Medical Therapy Should Be Bridged with ECMO Support as First Line MCS (PRO)

Sabrina P. Law, MD, Columbia University Medical Center, New York, NY, USA

5:00PM DEBATE: All Patients with Fulminant Myocarditis Failing Medical Therapy Should Be Bridged with ECMO Support as First Line MCS (CON)

Jacob Mathew, MD, Royal Children's Hospital, Melbourne, Australia

5:15 PM DEBATE: A Child with a Glenn Palliation with Severe Right Ventricular Systolic Dysfunction Should Be Bridged Medically to Transplant (PRO)

Kathleen Simpson, MD, St. Louis Children's Hospital, Saint Louis, MO, USA

5:30 PM DEBATE: A Child with a Glenn Palliation with Severe Right Ventricular Systolic Dysfunction Should Be Bridged Medically to Transplant (CON)

Antonio Amodeo, MD, Pediatric Hospital Bambino Gesù, Rome, Italy

5:45 PM Panel Discussion

SYMPOSIUM 33: Jukebox Jives: Going Beyond the Fundamentals of Antifungal Therapy (510BD)

Primary Audience: PHARM

Secondary Audience: HF/HTX, ID, LF/LTX, MCS, NHSAH, PEDS

Session Summary: Fungal infections are associated with high morbidity and mortality in thoracic transplant and MCS. This session will provide an overview of some less commonly encountered antifungal issues and provide guidance for clinicians enabling clinicians to make the most of currently available agents.

Chairs: Thais Gift, PharmD, BCPS and Fernanda Silveira, MD

4:15 PM Stuck on You: Reviewing Unique Antifungal Dosing in ECMO

Haifa Lyster, MSc, Royal Brompton and Harefield NHS Foundation Trust, Middlesex, United Kingdom

4:30 PM Q & A

4:35 PM Billie ‘Gene’: Pharmacogenomics of Antifungals

Christina Aquilante, PharmD, University of Colorado, Aurora, CO, USA

4:55 PM We Go Together: Synergy and Antagonism Among Antifungal Agents

Maureen Converse, PharmD, UF Health Shands, Gainesville, FL, USA

5:10 PM Q & A

5:15 PM A Change is Gonna Come Armamentarium Against Scedosporium and Fusarium

Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada

5:30 PM Q & A

5:35 PM Bitter Pill: Outside the [Pill] Box Antifungal Administration Strategies

Rickey A. Evans, PharmD, University of North Carolina Healthcare, Chapel Hill, NC, USA

5:50 PM Q & A

6:00 PM – 7:15 PM

POSTER SESSION 03

Information on ISHLT2020 Poster Sessions will be available in January 2020

MINI ORAL SESSIONS

Information on ISHLT2020 Mini Oral Sessions will be available in January 2020

Saturday, April 25, 2020

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 15: Considering Sex and Race: Strategies for the Non-Typical Transplant Recipient (511)

Primary Audience: HF/HTX

Secondary Audience: LF/LTX, MCS, NHSAH, PEDS

Session Summary: This symposium will focus on sex, gender, and race-specific strategies in HTX: differences in advanced HF therapies (MCS vs inotropic support, complications of MCS, status listing); differences in HTX and implications of sex and race matching; cardiovascular risk factors in women (traditional and non-traditional); pregnancy in HTX recipients (preconception considerations, timing, cardiac assessment, maternal and fetal complications, breastfeeding, immunosuppression, contraception, ethics); gender awareness.

Chairs: Yael Peled, MD and Marta Farrero, MD

7:00 AM The Woman in Red: Sex Differences in Advanced Heart Failure Therapies and Outcomes

Eileen M. Hsich, MD, Cleveland Clinic Foundation, Cleveland, OH, USA

7:15 AM Racial Differences in Advanced Heart Failure Therapies and Outcomes

Alanna A. Morris, MD, Emory University, Atlanta, GA, USA

7:30 AM Giving Birth After New Life: Pregnancy in Heart Transplant Recipients

Tuvia Ben Gal, MD, Rabin Medical Center, Petah Tikva, Israel

7:45 AM He/She/They: Gender Identity and Heart Transplant

Loreta Matheo, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

SUNRISE SYMPOSIUM 16: Early Markers for CLAD Development: Ready to Use or Discard? (510BD)

Primary Audience: LF/LTX

Secondary Audience: BSTR, PATH, PEDS

Session Summary: This session will give an update on the current status of blood and BAL biomarkers and early changes in pulmonary function, imaging, and pathology which might predict the development of CLAD and its specific phenotypes.

Chairs: Geert M. Verleden, MD, PhD, FERS and Federica Meloni, MD

7:00 AM Imaging, Pulmonary Function and Pathological Changes as Early Markers and Prognostic Sign for CLAD Phenotypes: How Predictable Are They?

Greg Snell, MD, The Alfred Hospital, Melbourne, Australia

7:20 AM Blood Biomarkers: Does Anything Stand at Present?

Sam S. Weigt, MD, UCLA Medical Center, Los Angeles, CA, USA

7:35 AM BAL Biomarkers: What's in the Name?

Angela Koutsokera, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland

7:50 AM Panel Discussion

SUNRISE SYMPOSIUM 17: I Never Thought I'd Live to Be a Hundred: Lessons Learned to Delay Transplantopathy (516BC)

Primary Audience: HF/HTX

Secondary Audience: PEDS, PHARM

Session Summary: In this session, lecturers will speak about complications that decrease long-term survival post heart transplant cardiac allograft vasculopathy and malignancy, focusing on updated clinical evidence to prevent their onset and/or delay their progression. Complications related to proliferation signal inhibitors and their impact to prevent long-term complications and improve survival post-transplant will be discussed.

Chairs: David A. Baran, MD and Elena Sandoval, MEBCTS

7:00 AM What’s Beyond Ten Years? A Definition for Transplantopathy

Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA

7:15 AM Facing the Facts: What Really Works and What Doesn’t to Prevent and Delay CAV?

Livia Goldraich, MD, Hospital de Clínicas Porto Alegre, Porto Alegre, Brazil

7:30 AM There Goes My Miracle: How Can We Prevent Post-Transplant Malignancies?

Sandrigo Mangini, MD, PhD, Heart Institute, Sao Paulo, Brazil

7:45 AM Panel Discussion

SUNRISE SYMPOSIUM 18: A Worthwhile Pursuit: Balancing Parallel Goals of Prolonged Life and Relief from Symptom Burden in Advanced Heart and Lung Disease (510AC)

Primary Audience: PH

Secondary Audience: HF/HTX, LF/LTX, NHSAH, PEDS, PHARM

Session Summary: Advanced cardiopulmonary disease (both the disease and treatment) has a devastating effect of quality of life (QoL). Palliative care support as a treatment option is very much underutilized in patients with end stage heart and lung disease both before and after transplantation. This session will focus on how to integrate palliative care and improve QoL both before and after transplantation. A panel discussion with all speakers will conclude this session.

Chairs: Sasha Storaasli, LCSW and Sandeep Sahay, MD

7:00 AM CASE PRESENTATION: End-Stage Cardiopulmonary Disease

Sandeep Sahay, MD, Houston Methodist Hospital, Houston, TX, USA

7:05 AM A Breath of Fresh Air: Management of Dyspnea in End Stage Heart/Lung Disease

Rebecca Colman, MD, University of Toronto, Toronto, ON, Canada

7:20 AM This Could Go a Couple of Ways: Understanding How Preoperative Expectations of Quality of Life After Transplant Measure Up with Actual Experience

Meghan Aversa, MD, New York Presbyterian at Columbia University, New York, NY, USA

7:35 AM A Shared Reality: Seeing Through the Lens by All Providers, Starting Early

Eric Nolley, MD, MS, Johns Hopkins, Baltimore, MD, USA

7:50 AM Panel Discussion

SUNRISE SYMPOSIUM 19: Coagulation Wars: Rogue Anticoagulation Strategies in Durable MCS (515ABC)

Primary Audience: PHARM

Secondary Audience: MCS, NHSAH

Session Summary: This session will focus on anticoagulation strategies and monitoring in adult and pediatric patients on durable mechanical circulatory support (MCS). Anticoagulation bridging approaches, reversal methods, and anticoagulation monitoring strategies will be discussed.

Chairs: Douglas L. Jennings, PharmD and Georgina Waldman, PharmD

7:00 AM Phantom Menace: Anticoagulation Bridging for Durable MCS

Tara Veasey, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA, USA

7:15 AM Q & A

7:20 AM A New Hope: Reversal of Bleeding for Durable MCS

Jean Connors, MD, Brigham and Women's Hospital, Boston, MA, USA

7:35 AM Q & A

7:40 AM Return of the Pharmacists: Pharmacist-Driven Anticoagulation for Durable MCS

Casandra Vale, BPharm, The Prince Charles Hospital, Queensland, Australia

7:55 AM Q & A

SUNRISE SYMPOSIUM 20: Challenges in the Field of Pediatric Heart Transplantation: Are We Solving Them? (513DEF)

Primary Audience: PEDS

Secondary Audience: HF/HTX, PATH, PHARM

Session Summary: This session aims to discuss the greatest controversies that pediatric transplant providers have debated over the last decade. There will be three main topics.

Chairs: Shahnawaz Amdani, MD and Estela Azeka, MD

7:00 AM Why Be Positive When You Can Be Negative? The Utility of Virtual Crossmatch

Linda J. Addonizio, MD, Columbia Presbyterian Medical Center, New York, NY, USA

7:15 AM Q & A

7:20 AM To Be Old and Wise or Young and Stupid: Biopsy vs. Novel Non-Invasive Means to Diagnose Rejection

Annalisa Angelini, MD, University of Padua, Padua, Italy

7:35 AM Q & A

7:40 AM Referring the Fontan for Advanced Therapies: When, How, Why?

Leigh C. Reardon, MD, UCLA Medical Center, Los Angeles, CA, USA

7:55 AM Q & A

8:15 AM – 10:00 AM

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

10:15 AM - 12:15 PM

PLENARY SESSION (511)

Primary Audience: ALL

Chairs: Joseph G. Rogers, MD and Peter M. Hopkins, FRACP

10:15 AM Awards Presentation

10:28 AM Caves Award Winner Encore Presentation

10:35 AM Featured Abstract

10:50 AM Featured Abstract

11:05 AM Featured Abstract

11:20 AM CASE PRESENTATION: President's Debate

Melissa Cousino, PhD, C.S. Mott Children's Hospital, Ann Arbor, MI, USA

11:25 AM PRESIDENT'S DEBATE: Psychosocial Issues Alone are A Contraindication to Transplantation (PRO)

Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

11:45 AM PRESIDENT'S DEBATE: Psychosocial Issues Alone are a Contraindication to Transplantation (CON)

Melanie D. Everitt, MD, Children's Hospital Colorado, Aurora, CO, USA

12:05 PM Debate Rebuttal (PRO)

Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

12:10 PM Debate Rebuttal (CON)

Melanie D. Everitt, MD, Children's Hospital Colorado, Aurora, CO, USA

12:15 PM – 2:00 PM

ORAL SESSIONS

Information on ISHLT2020 Oral Sessions will be available in January 2020

2:00 PM

Meeting Adjourns